StocktoriaFibroBiologics, Inc. FBLG
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M |
| Operating cash flow | -$16.4M | -$11.9M | -$6.4M | -$4.1M |
| Free cash flow | -$16.7M | -$12.1M | -$6.9M | — |
| Total assets | $9.6M | $16.4M | $11.8M | $4.8M |
| Total liabilities | $3.5M | $13.7M | $10.6M | $8.8M |
| Shareholders' equity | $6.2M | $2.7M | $1.3M | -$4.0M |
| Ratios | ||||
| Return on assets | -193.8% | -67.9% | -139.5% | -106.2% |
| Return on equity | -302.9% | -408.1% | -1315.6% | 128.2% |
| Current ratio | 3.61 | 1.12 | 1.00 | 0.37 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 15,997 | $21,116 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001958777 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.